Omniab Inc (OABI)

$1.51 -0.03 (-1.95%)
Market Cap 222.97M
Revenue (ttm) 18.67M
Net Income (ttm) -64.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -346.97%
Debt to Equity Ratio 0.00
Volume 372,700
Avg Vol 349,616
Day's Range N/A - N/A
Shares Out 144.78M
Stochastic %K 19%
Beta 0.17
Analysts Strong Sell
Price Target $7.33

Company Profile

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 250 7800
Address:
5980 Horton Street, Suite 600, Emeryville, United States
a36er
a36er Mar. 31 at 4:07 PM
$OABI Orders are filling too easy. I think we're heading lower.
0 · Reply
bearsoil
bearsoil Mar. 24 at 6:21 PM
$OABI Trading under 1.70 today makes for a good entry point. The introduction of the Omni Ultra Platform in late 2025 is a big thing. The Oeptide therapeutic space is huge. Investors are overlooking OABI because they are seeing low revenue along with the losses. Revenue growth will likely turn OABI profitable in 2028 or 9 Should have a good revenue base in the next year or two after that. By then the stock will be much higher than today.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 5:30 PM
$OABI RSI: 42.35, MACD: -0.0117 Vol: 0.09, MA20: 1.83, MA50: 1.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PlannedTrading101
PlannedTrading101 Mar. 10 at 5:19 PM
$OABI 2.50 - 3.00+ will come.
0 · Reply
a36er
a36er Mar. 5 at 5:23 AM
$OABI xPloration is probably going to have more legs to it than thought. Not a bad call.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 4 at 9:20 PM
$OABI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.11 up 8.33% YoY • Reported revenue of $8.38M down -22.47% YoY • OmniAb expects 2026 revenue between $25M and $30M, with costs and operating expenses from $80M to $85M. OmniAb anticipates ending 2026 with cash and cash equivalents of $30M to $35M.
0 · Reply
bearsoil
bearsoil Mar. 2 at 3:21 AM
$OABI IMVT1402 in phase 3 Should see results in 2027 This could be valuable. We should get an update on this weeks earnings call. OABI needs a mix of deals with both large and small companies. Large bios tend to want to pay upfront fees Smaller bios tend to want to backload in the form of royalties
0 · Reply
bearsoil
bearsoil Feb. 24 at 10:16 PM
$OABI Hopefully upcoming conference will gain some exposure for OABI. Volume has been low. Institutions have been holding. Any kind of good news should move the stock based on the decent amount of shorts. Would be nice if management could project earnings guidance out a little further.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 4:30 PM
$OABI RSI: 28.81, MACD: -0.0556 Vol: 0.12, MA20: 1.82, MA50: 1.90 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheSqueezeKingdom
TheSqueezeKingdom Feb. 17 at 3:00 PM
$MSTZ THIS is how we trade for financial freedom. $OABI $4.41 avg trade #11 is fun and make a lot of money having it.
0 · Reply
Latest News on OABI
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 4, 2026, 4:05 PM EST - 4 weeks ago

OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

OmniAb to Participate at the Leerink Partners Global Healthcare Conference

Feb 24, 2026, 8:00 AM EST - 6 weeks ago

OmniAb to Participate at the Leerink Partners Global Healthcare Conference

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Feb 19, 2026, 8:00 AM EST - 6 weeks ago

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

Dec 15, 2025, 4:05 PM EST - 4 months ago

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

Dec 4, 2025, 4:05 PM EST - 4 months ago

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

Nov 17, 2025, 5:23 PM EST - 5 months ago

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 4:05 PM EST - 5 months ago

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

OmniAb to Participate in Three Investor Conferences in November

Oct 16, 2025, 8:00 AM EDT - 6 months ago

OmniAb to Participate in Three Investor Conferences in November

OmniAb to Report Third Quarter 2025 Financial Results on November 4

Oct 14, 2025, 8:00 AM EDT - 6 months ago

OmniAb to Report Third Quarter 2025 Financial Results on November 4

OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 7 months ago

OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

OmniAb Announces $30 Million Private Placement

Aug 25, 2025, 7:00 AM EDT - 8 months ago

OmniAb Announces $30 Million Private Placement

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 6, 2025, 4:05 PM EDT - 8 months ago

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

OmniAb to Report Second Quarter 2025 Financial Results on August 6

Jul 16, 2025, 8:00 AM EDT - 9 months ago

OmniAb to Report Second Quarter 2025 Financial Results on August 6

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit

May 13, 2025, 4:05 PM EDT - 11 months ago

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:06 PM EDT - 11 months ago

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

OmniAb Introduces the xPloration® Partner Access Program

May 8, 2025, 4:05 PM EDT - 11 months ago

OmniAb Introduces the xPloration® Partner Access Program

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

May 5, 2025, 1:00 AM EDT - 1 year ago

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

OmniAb to Participate in Five Upcoming Investor Conferences

May 1, 2025, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Five Upcoming Investor Conferences

OmniAb Announces Two New Appointments to its Board of Directors

Apr 21, 2025, 8:00 AM EDT - 1 year ago

OmniAb Announces Two New Appointments to its Board of Directors

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 18, 2025, 4:05 PM EDT - 1 year ago

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

Feb 24, 2025, 8:00 AM EST - 1 year ago

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

OmniAb to Participate in Two Investor Conferences in March

Feb 3, 2025, 4:57 PM EST - 1 year ago

OmniAb to Participate in Two Investor Conferences in March

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

Jan 31, 2025, 11:09 AM EST - 1 year ago

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Dec 16, 2024, 4:15 PM EST - 1 year ago

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb to Participate in Two Investor Conferences in November

Oct 30, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in November

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Oct 22, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Third Quarter 2024 Financial Results on November 12

OmniAb to Participate in Two Investor Conferences in September

Aug 26, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in September

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

OmniAb to Report Second Quarter 2024 Financial Results on August 8

Jul 25, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Second Quarter 2024 Financial Results on August 8

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Jun 3, 2024, 4:05 PM EDT - 2 years ago

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

OmniAb to Participate in the Jefferies Global Healthcare Conference

May 20, 2024, 8:05 AM EDT - 2 years ago

OmniAb to Participate in the Jefferies Global Healthcare Conference

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

May 15, 2024, 4:05 PM EDT - 2 years ago

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

May 9, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

OmniAb to Participate in Five Investor Conferences in May

May 1, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Participate in Five Investor Conferences in May

OmniAb to Report First Quarter 2024 Financial Results on May 9

Apr 22, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Report First Quarter 2024 Financial Results on May 9

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 2 years ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

CNTN

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 20, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

Feb 26, 2024, 8:00 AM EST - 2 years ago

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

Dec 14, 2023, 4:30 PM EST - 2 years ago

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

Nov 9, 2023, 5:55 PM EST - 2 years ago

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 8:00 AM EST - 2 years ago

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

OmniAb Appoints Steve Love to its Board of Directors

Nov 1, 2023, 9:00 AM EDT - 2 years ago

OmniAb Appoints Steve Love to its Board of Directors

OmniAb Announces Agenda for its Research & Technology Virtual Event

Oct 31, 2023, 4:28 PM EDT - 2 years ago

OmniAb Announces Agenda for its Research & Technology Virtual Event

OmniAb to Hold Research & Technology Virtual Event on November 9

Oct 12, 2023, 8:00 AM EDT - 2 years ago

OmniAb to Hold Research & Technology Virtual Event on November 9

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 10, 2023, 4:05 PM EDT - 2 years ago

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

OmniAb Announces the Passing of Director Sunil Patel

Aug 7, 2023, 4:05 PM EDT - 2 years ago

OmniAb Announces the Passing of Director Sunil Patel

OmniAb to Report Second Quarter 2023 Financial Results on August 10

Jul 31, 2023, 8:00 AM EDT - 2 years ago

OmniAb to Report Second Quarter 2023 Financial Results on August 10

OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo

May 17, 2023, 4:05 PM EDT - 3 years ago

OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023, 7:00 AM EDT - 3 years ago

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

a36er
a36er Mar. 31 at 4:07 PM
$OABI Orders are filling too easy. I think we're heading lower.
0 · Reply
bearsoil
bearsoil Mar. 24 at 6:21 PM
$OABI Trading under 1.70 today makes for a good entry point. The introduction of the Omni Ultra Platform in late 2025 is a big thing. The Oeptide therapeutic space is huge. Investors are overlooking OABI because they are seeing low revenue along with the losses. Revenue growth will likely turn OABI profitable in 2028 or 9 Should have a good revenue base in the next year or two after that. By then the stock will be much higher than today.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 5:30 PM
$OABI RSI: 42.35, MACD: -0.0117 Vol: 0.09, MA20: 1.83, MA50: 1.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PlannedTrading101
PlannedTrading101 Mar. 10 at 5:19 PM
$OABI 2.50 - 3.00+ will come.
0 · Reply
a36er
a36er Mar. 5 at 5:23 AM
$OABI xPloration is probably going to have more legs to it than thought. Not a bad call.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 4 at 9:20 PM
$OABI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.11 up 8.33% YoY • Reported revenue of $8.38M down -22.47% YoY • OmniAb expects 2026 revenue between $25M and $30M, with costs and operating expenses from $80M to $85M. OmniAb anticipates ending 2026 with cash and cash equivalents of $30M to $35M.
0 · Reply
bearsoil
bearsoil Mar. 2 at 3:21 AM
$OABI IMVT1402 in phase 3 Should see results in 2027 This could be valuable. We should get an update on this weeks earnings call. OABI needs a mix of deals with both large and small companies. Large bios tend to want to pay upfront fees Smaller bios tend to want to backload in the form of royalties
0 · Reply
bearsoil
bearsoil Feb. 24 at 10:16 PM
$OABI Hopefully upcoming conference will gain some exposure for OABI. Volume has been low. Institutions have been holding. Any kind of good news should move the stock based on the decent amount of shorts. Would be nice if management could project earnings guidance out a little further.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 4:30 PM
$OABI RSI: 28.81, MACD: -0.0556 Vol: 0.12, MA20: 1.82, MA50: 1.90 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheSqueezeKingdom
TheSqueezeKingdom Feb. 17 at 3:00 PM
$MSTZ THIS is how we trade for financial freedom. $OABI $4.41 avg trade #11 is fun and make a lot of money having it.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 7:17 PM
$OABI Current Stock Price: $1.70 Contracts to trade: $2.5 OABI Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 49% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
a36er
a36er Feb. 11 at 11:31 PM
$OABI Gotham has built up quite the passive position and the market sleeps.
0 · Reply
KellyPinell398
KellyPinell398 Feb. 11 at 3:15 PM
$OABI OmniAb; antibody discovery platform; biotech services; revenue tied to partner milestones and royalties; valuation hinges on platform validation.
0 · Reply
no_cry
no_cry Feb. 7 at 12:49 AM
$OABI what is up with skyrocket and then back down
2 · Reply
a36er
a36er Feb. 6 at 3:23 PM
$OABI Not really understanding the price action here, Immunovant's call was right on track. Unrelated to revenue for OmniAB but Roivant is about to put yet another bow on a spin-off with Pfizer (Priovant). I've been adding.
0 · Reply
a36er
a36er Feb. 5 at 6:25 AM
$OABI Towerview has been adding. Some pretty "smart" money is getting behind this company.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 5:44 PM
$OABI RSI: 62.07, MACD: 0.0200 Vol: 0.05, MA20: 1.91, MA50: 1.89 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Landomos
Landomos Jan. 26 at 1:29 PM
$OABI
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 7:33 AM
$OABI
0 · Reply
jranz10
jranz10 Jan. 23 at 11:54 PM
$OABI I’m in .. adding more monday lets go
0 · Reply
Landomos
Landomos Jan. 8 at 2:20 PM
$OABI $4.00?
0 · Reply